Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Torsten Tonn"'
Autor:
Romy Kronstein-Wiedemann, Sarah Blecher, Madeleine Teichert, Laura Schmidt, Jessica Thiel, Markus M. Müller, Jörn Lausen, Richard Schäfer, Torsten Tonn
Publikováno v:
Leukemia. 37:1126-1137
The ABO blood group (BG) system is of great importance for blood transfusion and organ transplantation. Since the same transcription factors (TFs) and microRNAs (miRNAs) govern the expression of ABO BG antigens and regulate erythropoiesis, we hypothe
Autor:
Jordi Pfeifer Serrahima, Congcong Zhang, Pranav Oberoi, Malena Bodden, Jasmin Röder, Claudia Arndt, Anja Feldmann, Anne Kiefer, Maren Prüfer, Ines Kühnel, Torsten Tonn, Michael Bachmann, Winfried S. Wels
Publikováno v:
Cancer Immunology, Immunotherapy.
Chimeric antigen receptor (CAR)-engineered immune effector cells constitute a promising approach for adoptive cancer immunotherapy. Nevertheless, on-target/off-tumor toxicity and immune escape due to antigen loss represent considerable challenges. Th
Autor:
Peter Milanov, Lars C Vermaat, Clemens H. M. Kocken, Erica M. Pasini, Jessica Thiel, Romy Kronstein-Wiedemann, Torsten Tonn, Onny Klop, Claudia Ruhland
Publikováno v:
Experimental Hematology
Highlights • miR-26a and miR-30a knockdowns promote differentiation in Fy-transduced K562 cell lines. • miR-26a and miR-30a knockdowns promote enucleation in Fy-transduced K562 cell lines. • Data denote an interplay in the mode of action of miR
Autor:
M I Strecker, F Strassheimer, Winfried S. Wels, Joachim P. Steinbach, J Reul, Michael C. Burger, Christian J. Buchholz, Patrick N. Harter, K Wlotzka, Torsten Tonn
Publikováno v:
Neuro Oncol
BACKGROUND Glioblastoma (GB) is the most common primary brain tumor which is characterized by low immunogenicity of tumor cells and prevalent immunosuppression in the tumor microenvironment (TME). Since expression of PD-L1 on GB cells has been descri
Autor:
Winfried S. Wels, Jiri Eitler, Laurent Boissel, Torsten Tonn, Natalie Wotschel, Hans G. Klingemann, Nicole Miller
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
BackgroundOn encountering a susceptible target, natural killer (NK) cells mediate cytotoxicity through highly regulated steps of directed degranulation. Cytotoxic granules converge at the microtubule organizing center and are polarized toward the imm
Autor:
Daianne Maciely Carvalho Fantacini, Kelen C. R. Malmegrim, Dimas Tadeu Covas, J. Eitler, Renata Nacasaki Silvestre, Kamilla Swiech, Virgínia Picanço-Castro, Torsten Tonn
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss, Pp 418-(2020)
Autor:
Joachim P. Steinbach, Winfried S. Wels, Patrick N. Harter, Christian J. Buchholz, J Reul, Michael C. Burger, F Strassheimer, Torsten Tonn, M I Strecker
Publikováno v:
E-Poster Presentations.
Glioblastoma (GB) is the most common primary brain tumor which is characterized by a low immunogenicity of tumor cells and a prevalent immunosuppression in the tumor microenvironment (TME). Since expression of PD-L1 on GB cells has been described, im
Autor:
Winfried S. Wels, M C Demes, M I Strecker, Tijna Alekseeva, Lisa Sevenich, IC Mildenberger, Peter J. Wild, Michael C. Burger, Karl-Heinz Plate, Joachim P. Steinbach, Jadranka Macas, Yvonne Reiss, F Strassheimer, Patrick N. Harter, Torsten Tonn
Publikováno v:
E-Poster Presentations.
Background Checkpoint inhibitors as well as adoptive cell therapy hold great promise for cancer therapy and encouraging treatment responses have already been demonstrated in different cancer indications. Glioblastoma (GB) is the most common and aggre
Autor:
Marcus Odendahl, Julia Manderla, Sarah Matko, Maria Bonsack, Martin Bornhäuser, Torsten Tonn, Marc Schmitz
Publikováno v:
European Journal of Immunology. 48:1400-1411
Antigen-specific T cells isolated from healthy individuals (HIs) have shown great therapeutic potential upon adoptive transfer for the treatment of viremia in immunosuppressed patients. The lack of comprehensive data on the prevalence and characteris
Autor:
Michael C. Burger, Winfried S. Wels, Patrick N. Harter, Yvonne Reiss, Iris Mildenberger, Peter J. Wild, Karl-Heinz Plate, Joachim P. Steinbach, M I Strecker, Tijna Alekseeva, M C Demes, Jadranka Macas, F Strassheimer, Torsten Tonn, Lisa Sevenich
Publikováno v:
Neuro-Oncology. 23:ii15-ii15
INTRODUCTION Checkpoint inhibitors as well as adoptive cell therapy hold promise for cancer therapy and encouraging treatment responses have already been demonstrated in different cancer indications. Glioblastoma (GB) is the most common and aggressiv